SEC Form 4 · accession 0001171843-17-001364
Sucampo Pharmaceuticals, Inc. · SCMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Lichtlen
Officer — Chief Medical Officer
Period of report
Mar 6, 2017
Accepted (ET)
Mar 8, 2017 · 5:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001365216
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1 | Mar 6, 2017 | A | 24,000 | $0.00 | A | 24,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $11.85 | Mar 6, 2017 | A | 45,000 | A | — | Mar 2, 2027 | Class A Common Stock | 45,000 | 314,400 | D |
Explanation of responses
- F1Common stock granted consists of restricted stock units that vest on March 2, 2020.
- F2The option will vest over a four-year period, with 25% vesting on March 2, 2018 and the remaining 75% vesting in equal monthly increments over the three-year period thereafter.